Daniel Lochner - 26 Aug 2021 Form 4 Insider Report for Oyster Point Pharma, Inc.

Role: Chief Financial Officer
Signature: /s/ Brandon Fenn, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 26 Aug 2021
Net transactions value: $0
Form type: 4
Filing time: 30 Aug 2021, 16:52:44 UTC
Previous filing: 29 Jul 2021
Next filing: 07 Sep 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OYST	Employee Stock Option (Right to Buy)	Award	$0	-45,000	-50%	$0.000000	45,000	26 Aug 2021	Common Stock	45,000	$13.78	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Options granted on August 26, 2021 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. One-fourth (1/4) of the options shall vest and become exercisable on August 26, 2022 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date.

Content

Options granted on August 26, 2021 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. One-fourth (1/4) of the options shall vest and become exercisable on August 26, 2022 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date.